A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8245.
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2011
At a glance
- Drugs MK 8245 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 10 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Sep 2009 Planned end date changed from 1 Aug 2009 to 1 Sep 2009 as reported by ClinicalTrials.gov.
- 23 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.